Hirudoid (Chondroitin Polysulfate)

Hirudoid is indicated for several superficial conditions where reduced clot formation and swelling are desired. It is commonly used to manage superficial thrombophlebitis, bruises, hematomas, and postoperative swelling of the skin and underlying tissues.

• Superficial thrombophlebitis: reduces inflammation and limits clot extension in small veins.
• Contusions and bruises: helps diminish discoloration and swelling after minor trauma.
• Hematoma resolution: supports reabsorption of localized blood collections under the skin.
• Post‑operative edema: applied to surgical sites to lessen swelling and discomfort.
• Minor skin inflammation: may be used on irritated areas where vascular congestion is present.

• Chondroitin polysulfate exerts its effect by interfering with the coagulation cascade and by modulating inflammatory pathways in the microvasculature. The molecule binds to endothelial surfaces, inhibiting thrombin and factor Xa activity, which reduces fibrin formation. Simultaneously, it suppresses the release of pro‑inflammatory mediators such as histamine and prostaglandins, leading to decreased vascular permeability and edema in superficial vessels. These combined actions contribute to the observed antithrombotic and anti‑edematous properties when applied topically.

Topical application of Hirudoid may be associated with local skin reactions and, rarely, systemic effects.

Common

• Mild erythema or redness at the application site.
• Transient itching or mild pruritus.
• Slight burning sensation that resolves within minutes.

Serious

• Allergic contact dermatitis with spreading rash.
• Severe skin ulceration or necrosis.
• Systemic hypersensitivity reactions such as urticaria or angioedema.

When using Hirudoid, certain precautions help minimize adverse reactions and ensure safe use.

• Avoid application on broken, infected, or severely irritated skin.
• Do not use under occlusive dressings unless directed by a healthcare professional.
• Keep the product away from eyes, mucous membranes, and open wounds.
• Discontinue use and seek medical advice if signs of an allergic reaction develop.
• Store at room temperature, protected from excessive heat and direct sunlight.
• Pregnant or breastfeeding individuals should consult a physician before use.
• Children under 12 years should use only under supervision.

Hirudoid can interact with other topical agents or systemic medications that affect coagulation or skin integrity.

Avoid

• Concurrent use with other topical anticoagulants (e.g., heparin creams) without medical guidance.
• Application together with potent irritant or drying agents such as high‑strength corticosteroids.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) may increase bleeding tendency if large skin areas are treated.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied topically in the same region.
• Herbal or homeopathic skin preparations that contain salicylates or other anticoagulant compounds.